Agnes C Kant
Overview
Explore the profile of Agnes C Kant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
9
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
de Feijter M, van Gelder M, Vissers L, Kant A, Woestenberg P
Pharmacoepidemiol Drug Saf
. 2023 Nov;
33(1):e5724.
PMID: 37946587
Purpose: Pregnant women are at higher risk of severe illness and adverse pregnancy outcomes due to a SARS-CoV-2 infection, which can be prevented by vaccination. Observational studies are needed to...
3.
Woestenberg P, de Feijter M, Bergman J, Lutke L, Passier A, Kant A
Birth Defects Res
. 2023 Sep;
115(18):1746-1757.
PMID: 37737482
Background: Information regarding the risk of early pregnancy COVID-19 vaccination on the development of major congenital anomalies in the offspring is still limited. Here, we study the association between any...
4.
van Hunsel F, Kant A, van Puijenbroek E
Ned Tijdschr Geneeskd
. 2014 May;
158:A6651.
PMID: 24846110
After media attention on the possible risks of thromboembolic complications associated with the use of cyproterone/ethinylestradiol (Diane-35 and generics), the Netherlands Pharmacovigilance Centre Lareb received a large number of reports...
5.
van Balveren-Slingerland L, Rumke H, Kant A
Ned Tijdschr Geneeskd
. 2014 Feb;
158:A6841.
PMID: 24518843
Objective: Review of case reports of possible adverse events following immunization (AEFI) after vaccination with an influenza vaccine in the past three years. Design: Descriptive, retrospective. Method: Lareb (Netherlands Pharmacovigilance...